Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome
Bismuth-based drugs have been used primarily to treat ulcers caused by <i>Helicobacter pylori</i> and other gastrointestinal ailments. Combined with antibiotics, these drugs also possess synergistic activity, making them ideal for multiple therapy regimens and overcoming bacterial resist...
Main Authors: | Jânia dos Santos Rosário, Fábio Henrique Moreira, Lara Hewilin Fernandes Rosa, Wendell Guerra, Priscila Pereira Silva-Caldeira |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/28/15/5921 |
Similar Items
-
The benefit of the bismuth add-on to the 2-week clarithromycin-based triple regimen for Helicobacter pylori eradication: a propensity score-matched retrospective study
by: Da Wit Shin, et al.
Published: (2023-03-01) -
Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed <i>Helicobacter pylori</i> Infection as 14 Days of Bismuth-Based Quadruple Therapy
by: Sang-Gon Moon, et al.
Published: (2022-07-01) -
A Simplified Low-Dose 10-Day Quadruple Therapy with a Galenic Formulation of Bismuth Salicylate Is Highly Effective for <i>Helicobacter pylori</i> Eradication
by: Maria Pina Dore, et al.
Published: (2023-01-01) -
Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for <i>Helicobacter pylori</i> Eradication: A Pilot Study
by: Senlin You, et al.
Published: (2024-02-01) -
Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
by: Arash Kazemi, et al.
Published: (2023-09-01)